Literature DB >> 15164098

Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells.

R Inoue1, K A Moghaddam, M Ranasinghe, Y Saeki, E A Chiocca, R Wade-Martins.   

Abstract

The expression of genes from genomic loci can be relatively complex, utilizing exonic, intronic and flanking sequences to regulate tissue and developmental specificity. Infectious bacterial artificial chromosomes (iBACs) have been shown to deliver and express large genomic loci (up to 135 kb) into primary cells for functional analyses. The delivery of large genomic DNA inserts allows the expression of complex loci and of multiple splice variants. Herein, we demonstrate for the first time that an iBAC will deliver and correctly express in human glioma cells the entire CDKN2A/CDKN2B genomic region, which encodes for at least three important cell-cycle regulatory proteins (p16(INK4a), p14(ARF) and p15(INK4b)). Two of these proteins are expressed from overlapping genes, utilizing alternative splicing and promoter usage. The delivered locus expresses each gene at physiological levels and cellular responses (apoptosis versus growth arrest) occur dependent on cellular p53 status, as expected. The work further demonstrates the potential of the iBAC system for the delivery of genomic loci whose expression is mediated by complex splicing and promoter usage both for gene therapy applications and functional genomics studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164098     DOI: 10.1038/sj.gt.3302284

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  15 in total

Review 1.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

Review 2.  Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.

Authors:  J Robert Kane; Jason Miska; Jacob S Young; Deepak Kanojia; Julius W Kim; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

3.  Assessing the functional characteristics of synonymous and nonsynonymous mutation candidates by use of large DNA constructs.

Authors:  A M Eeds; D Mortlock; R Wade-Martins; M L Summar
Journal:  Am J Hum Genet       Date:  2007-03-08       Impact factor: 11.025

4.  Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin.

Authors:  Masataka Suzuki; Kazue Kasai; Yoshinaga Saeki
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Physiological transgene regulation and functional complementation of a neurological disease gene deficiency in neurons.

Authors:  Pier Paolo Peruzzi; Sean E Lawler; Steve L Senior; Nina Dmitrieva; Pauline A H Edser; Davide Gianni; E Antonio Chiocca; Richard Wade-Martins
Journal:  Mol Ther       Date:  2009-04-07       Impact factor: 11.454

6.  ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression.

Authors:  Masataka Suzuki; Kazue Kasai; Akihiro Ohtsuki; Jakub Godlewski; Michal O Nowicki; E Antonio Chiocca; Yoshinaga Saeki
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

Review 7.  Design and application of oncolytic HSV vectors for glioblastoma therapy.

Authors:  Paola Grandi; Pierpaolo Peruzzi; Bonnie Reinhart; Justus B Cohen; E Antonio Chiocca; Joseph C Glorioso
Journal:  Expert Rev Neurother       Date:  2009-04       Impact factor: 4.618

8.  Gene- and viral-based therapies for brain tumors.

Authors:  Kaveh Asadi-Moghaddam; E Antonio Chiocca
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 9.  Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy.

Authors:  S P Simna; Zongchao Han
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.676

10.  Regulated expression of a transgene introduced on an oriP/EBNA-1 PAC shuttle vector into human cells.

Authors:  Hanne A Askautrud; Elisabet Gjernes; Gro L Størvold; Mona M Lindeberg; Jim Thorsen; Hans Prydz; Eirik Frengen
Journal:  BMC Biotechnol       Date:  2009-10-16       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.